Article Cited by others

ORIGINAL ARTICLE

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients

Wang Yue, Dai Bo, Ye Ding-Wei

Year : 2017| Volume: 19| Issue : 2 | Page no: 178-183

   This article has been cited by
 
1 Comparison of Testosterone and Prostate-Specific Antigen Nadir Value between Castration Resistant Prostate Cancer and Non-Castration Resistant Prostate Cancer Patients after Androgen Deprivation Therapy - A Single Center Study in Indonesia
Ferry Safriadi, Sawkar Vijay Pramod, Bernard Partogu, Zola Wijayanti
Open Access Macedonian Journal of Medical Sciences. 2022; 10(B): 1014
[Pubmed]  [Google Scholar] [DOI]
2 Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications
Lennart J. van Winden,Mirthe Lanfermeijer,Annemieke C. Heijboer,Olaf van Tellingen,Andries M. Bergman,Henk G. van der Poel,Niels Jonker,Huub H. van Rossum
Clinica Chimica Acta. 2021; 521: 70
[Pubmed]  [Google Scholar] [DOI]
3 Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer
Daniel J George,David P Dearnaley
Future Oncology. 2021;
[Pubmed]  [Google Scholar] [DOI]
4 Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review
Shengri Tian,Zhen Lei,Zuo Gong,Zhonghai Sun,Dongyuan Xu,Minhu Piao
Cancer Cell International. 2020; 20(1)
[Pubmed]  [Google Scholar] [DOI]
5 Discordance between testosterone measurement methods in castrated prostate cancer patients
Mélanie Rouleau,Francis Lemire,Michel Déry,Benoît Thériault,Gabriel Dubois,Yves Fradet,Paul Toren,Chantal Guillemette,Louis Lacombe,Laurence Klotz,Fred Saad,Dominique Guérette,Frédéric Pouliot
Endocrine Connections. 2019; : 132
[Pubmed]  [Google Scholar] [DOI]
6 THE ROLE OF ADIPOSE TISSUE WITH PARTICULAR EMPHASIS ON CYTOKINES IN THE PATHOGENESIS OF NEOPLASTIC DISEASES
Jakub Warakomski,Lucyna Sieminska
Wiadomosci Lekarskie. 2019; 72(8): 1551
[Pubmed]  [Google Scholar] [DOI]
7 Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel
Keisuke Ando,Shinichi Sakamoto,Nobushige Takeshita,Ayumi Fujimoto,Maihulan Maimaiti,Shinpei Saito,Pae Sanjyon,Yusuke Imamura,Nobuo Sato,Akira Komiya,Koichiro Akakura,Tomohiko Ichikawa
The Prostate. 2019;
[Pubmed]  [Google Scholar] [DOI]
8 Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
Yinghao Sun,Liping Xie,Xu Tao,Jørn S. Jakobsen,Weiqing Han,Per S. Sørensen,Xiao Feng Wang
Asian Journal of Urology. 2019;
[Pubmed]  [Google Scholar] [DOI]
9 Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis
Mélanie Claps,Fausto Petrelli,Orazio Caffo,Vito Amoroso,Elisa Roca,Alessandra Mosca,Francesca Maines,Sandro Barni,Alfredo Berruti
Clinical Genitourinary Cancer. 2018;
[Pubmed]  [Google Scholar] [DOI]
10 Sex steroids in the tumor microenvironment and prostate cancer progression
Clovis Boibessot,Paul Toren
Endocrine-Related Cancer. 2018; 25(3): R179
[Pubmed]  [Google Scholar] [DOI]

 

Read this article